This report provides exclusive insights into the COVID-19 impact on the Anticoagulant Reversal Drugs Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Anticoagulant Reversal Drugs Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Anticoagulant Reversal Drugs Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on the anticoagulant reversal drugs market provides an in-depth analysis of segments and
sub-segments in the global as well as regional anticoagulant reversal drugs
market. The study also highlights the impact of drivers, restraints, and macro
indicators on the global and regional anticoagulant reversal drugs market over the
short term as well as long term. The report is a comprehensive presentation of
trends, forecast and dollar values of the global anticoagulant reversal drugs
market. According to the report, the global anticoagulant reversal drugs market
is projected to grow at a CAGR of 11.5 % over the forecast period of 2019-2025.
Anticoagulant reversal drugs are required when there is a need to
neutralize anticoagulant therapy in a situation, where there is a complication
of bleeding such as in heart attack or stroke. Andexxa is the only drug
launched by the Portola Pharmaceuticals Inc. that is used for reversing the
effect of factor Xa inhibitors. It is used, when people are suffering from
severe complications from blood clots. Additionally, in 2019, Portola
Pharmaceuticals Inc. has launched Andexxa with the name Ondexxya in Europe and
there are fewer side effects of it. The objective of this launch is to manage
the availability of Andexxa to as many hospitals and patients as possible to
meet their higher requirements. This will help to increase the sale of the
Andexxa in the hospital, which in turn boosts the anticoagulant reversal drugs.
The rise in the prevalence of atrial fibrillation and
cardiovascular disease is the factor, which is likely to boost this market. As
it is found that cardiovascular disease mainly found in the adult. For
instance, about 40 % of the adult population in the United States were
diagnosed with a cardiovascular condition in 2018. Therefore, the growing aging
population is anticipated to experience the rapid growth of the market. On the
other hand, the approval of blockbuster drugs in recent years such as Andexxa
and a strong pipeline are contributing to the growth of the market. The
increasing focus of the company in the R&D activities which, in turn,
propels the market. The government is taking initiatives towards the healthcare
expenditure, which helps to drive for the market. However, the availability of
the high cost of the patent drugs yet remains one of the major restraints to
this market. Moreover, many companies are taking initiative to launch the drug,
which is used for reversing the effect of factor Xa inhibitors offer favorable
opportunities in this market.
Geographically, North America is the dominant region in this market
and is expected to hold the maximum market share in the forecast period owing
to increasing drug approval by the USFDA as well as involving in the prevention
program of the blood disorder such as by Centers for Disease Control and
Prevention. On another hand, Europe holds the second-largest market share in
this market due to the recent launch of the Ondexxya and the continuous growth
of the R&D activities by the companies.
The report on global anticoagulant reversal drugs market covers
segments such as product type, and distribution channel. On the basis of
product type, the sub-markets include prothrombin complex concentrates, vitamin
k, protamine, tranexamic acid, idarucizumab, andexxa, and other product types.
On the basis of distribution channel, the sub-markets include hospital
pharmacies, retail pharmacies, and others distribution channels.
The report provides profiles of the companies in the market such
as Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal
Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG,
Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc.
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of the anticoagulant
reversal drugs market. Moreover, the study highlights current market trends and
provides forecast from 2019-2025. We also have highlighted future trends in the
market that will affect the demand during the forecast period. Moreover, the
competitive analysis given in each regional market brings an insight into the
market share of the leading players.